Gamma Synuclein Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gamma-synuclein (SNCB) is a member of the synuclein protein family that includes alpha-synuclein and beta-synuclein. While less studied than alpha-synuclein, gamma-synuclein has been implicated in neurodegenerative diseases and cancer progression.
Gamma-Synuclein
| Property | Value |
|---------|-------|
| **Protein Name** | Gamma-Synuclein |
| **Gene** | SNCG |
| **UniProt** | P37841 |
| **Molecular Weight** | ~14 kDa (127 amino acids) |
| **Subcellular Localization** | Cytoplasm, presynaptic terminals, nucleus |
| **Protein Family** | Synuclein family |
| **Aliases** | BCSG1, Synoretin |
Gamma-synuclein (encoded by the SNCG gene) is the third member of the synuclein protein family, which also includes alpha-synuclein (associated with Parkinson's disease) and beta-synuclein[1]. While initially discovered as a breast cancer marker (BCSG1), gamma-synuclein is also expressed in the peripheral and central nervous systems[2]. Its role in neurodegeneration is complex - it may be protective in some contexts while contributing to pathology in others[3].
Gamma-synuclein shares structural features with other synucleins[4]:
- N-terminal region (1-60): Contains imperfect repeats of the sequence KTKEGV, forming an amphipathic alpha-helix
- Non-Aβ component (NAC) region (61-95): Lacks the full NAC sequence present in alpha-synuclein
- C-terminal acidic tail (96-127): Highly acidic region involved in protein interactions
Unlike alpha-synuclein, gamma-synuclein lacks the central hydrophobic region that drives amyloid fibril formation.
Gamma-synuclein exhibits molecular chaperone function[5]:
- Anti-aggregation activity: Inhibits alpha-synuclein and beta-synuclein aggregation
- Heat shock protein-like: Can protect cells from proteotoxic stress
- Anti-apoptotic: May prevent programmed cell death
In the normal brain, gamma-synuclein is expressed in[6]:
- Peripheral nervous system: Higher expression than central nervous system
- Presynaptic terminals: Localized to synaptic vesicles
- Substantia nigra: Lower levels than alpha-synuclein
- Olfactory bulb: Moderate expression
- Cancer biology: Overexpressed in breast, ovarian, and prostate cancers
- Cell proliferation: Promotes cell growth and survival
- Metastasis: Associated with cancer progression
Gamma-synuclein in PD is complex and context-dependent[7]:
- Protective role: May inhibit alpha-synuclein aggregation
- Expression changes: Altered in PD substantia nigra
- Lewy bodies: Generally not a major component
- Expression: Elevated in DLB brains
- Co-aggregation: May co-aggregate with alpha-synuclein
- Diagnostic marker: Potential biomarker
- Inclusions: Found in some glial cytoplasmic inclusions
- Pathological role: Less prominent than alpha-synuclein
The relationship between gamma-synuclein and alpha-synuclein is nuanced[8]:
| Interaction |
Effect |
| Co-expression |
Reduces alpha-synuclein aggregation |
| Binding |
Prevents fibril formation |
| Sequestration |
May redirect aggregation |
Gamma-synuclein (BCSG1) has been studied as a cancer biomarker[9]:
- Breast cancer: Serum levels elevated in metastatic disease
- Ovarian cancer: Potential diagnostic marker
- Prostate cancer: Associated with aggressiveness
- Target: May be therapeutic target in certain cancers
- Neuroprotection paradox: Anti-cancer vs. neuroprotective functions
Potential therapeutic strategies[10]:
- Enhancement: Increase gamma-synuclein expression to protect against alpha-synuclein toxicity
- Mimetics: Develop small molecules that mimic its anti-aggregation activity
- Gene therapy: AAV-mediated expression
- Inhibition: Suppress gamma-synuclein in metastatic cancer
- Antibody therapy: Target overexpressing tumors
- Ahmad M, et al. (2007). "Gamma-synuclein in Parkinson's disease." J Neurosci Res.[1]
- Buchman VL, et al. (1998). "Synucleins in neurodegenerative disease." Brain Res Bull.[2]
- Park SH, et al. (2009). "Gamma-synuclein and neuroprotection." Mol Cell Neurosci.[3]
The study of Gamma Synuclein Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Spillantini MG, et al. (1997). "Gamma-synuclein and neurodegenerative diseases." Trends Neurosci. PMID:9177773
- George JM (2002). "The synucleins." Genome Biol. PMID:11983058
- Surguchov A (2008). "Synucleins: functionally relevant." J Mol Neurosci. PMID:18566911
- Beyer K, et al. (2009). "Gamma-synuclein and neurodegeneration." Neurol Sci. PMID:19370438
- Patel SS, et al. (2011). "Gamma-synuclein inLewy body disorders." Acta Neuropathol. PMID:21503959
- Hashimoto M, et al. (2001). "Gamma-synuclein: a neurodegenerative disease protein." Neurochem Res 26(8): 855-860. PMID:11565607
- Nakai M, et al. (2007). "Gamma-synuclein modifies neuronal metabolism." Neurobiol Aging 28(1): 34-41. PMID:16500065
- Surguchov A. (2008). "Molecular and cellular biology of synucleins." Int Rev Cell Mol Biol 265: 1-59. PMID:18063572